A Phase 2 interventional study of MZE829 in Proteinuric Kidney Disease, sponsored by Maze Therapeutics. Recruiting at 79 sites in 3 countries. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Maze Therapeutics · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.
Maze Therapeutics is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria defined in protocol apply.
Cohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes
Drug: MZE829
Capsules for oral administration
Safety and tolerability as assessed by incidence of adverse events (AEs)
Time frame: Baseline to Week 12
Percent participants with ≥30% reduction from baseline in UACR at Week 12
Time frame: Baseline to Week 12
Geometric mean plasma drug concentrations
Time frame: Baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maze Therapeutics